HIV — bridging the research gap in Sydney

The meeting is expected to draw around 5,000 delegates and has received a record number of abstracts (3,200) — a 50% increase from IAS 2005 in Rio de Janeiro, Brazil. Despite criticism over the years that IAS meetings lack scientific and clinical focus, this year promises to be different.

Among highlights at the meeting will be the latest data for new drugs in both old and new classes, as well as new data for several drugs in development from early phase trials. The results of three phase III randomised trials, DUET-1, DUET-2, and TITAN, published in this week's issue of The Lancet, should help to alleviate the unmet clinical need of patients who have exhausted all other treatment options.

For the free full text of the article, see here. Remember that you have to register with The Lancet to view their content. Registration is quick and free.